Summary:
A Phase 4 open label study to evaluate vedolizumab IV dose optimization on treatment outcomes in nonresponders with moderately to severly active ulcerative colitis
Qualified Participants Must:
• Be male or female 18-85 yrs old
•
Diagnosis of UC at least 1 month prior to screening
•
Moderately to severly active UC
•
Inadequate response with, lost response to or intoerance of at least 1 of the following agents: immunomodulators, corticosteroids, or TNF-a antagonist or TNF-a naive
Qualified Participants May Receive:
Compensation for their time and travel. Eligible participants will receive the study treatment and study-related care at no cost.